Biotech

All Articles

Merck stops period 3 TIGIT test in lung cancer for impossibility

.Merck &amp Co.'s TIGIT program has actually endured one more obstacle. Months after shuttering a st...

After a hard year, Exscientia folds right into Recursion

.After a year described by pipeline cuts, the shift of its own chief executive officer and unemploym...

Cullinan, after $25M bargain, return bispecific to Harbour

.Cullinan Therapeutics was made an impression on enough with Port BioMed's bispecific immune system ...

A better consider Intense Biotech's Fierce 15

.In this week's incident of "The Best Line," we're diving into Intense Biotech's annual Brutal 15 sp...

Lilly faces stage 2 breakdown of tau-targeting med

.The confetti is still soaring from Eli Lilly's celebration celebrating the approval of Alzheimer's ...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of considerable leadership hirings, firings...

Lykos will certainly talk to FDA to reexamine its decision complying with being rejected of MDMA treatment for post-traumatic stress disorder

.Observing an unsatisfactory revealing for Lykos Therapeutics' MDMA prospect for post-traumatic stre...

AN 2 halves head count, ceases stage 3 trial after information let down

.AN2 Therapies is reviewing its company in response to dull midphase data, vowing to lay off half it...

Merck pays for $700M for bispecific, spying autoimmune opening and possibility to challenge Amgen in cancer

.Merck &amp Co. is actually paying $700 million in advance to test Amgen in a blood stream cancer ce...

Gilead pays J&ampJ $320M to exit licensing package for seladelpar

.With Gilead Sciences about to an FDA choice for its liver condition drug seladelpar, the provider h...